Merck is undergoing a strategic restructuring, resulting in immediate job cuts in administration, sales, and research as part of a plan to save $3 billion by 2027.

Zusduri is the first non-surgical therapy to be approved for NMIBC, setting a new standard for the indication.

Raleigh’s Verona Pharma acquired by Merck for $10 billion as maker of COPD treatment Ohtuvayre merges with pharmaceutical company with growing Durham, NC footprint ...

Merck to acquire Verona Pharma for $10B, gaining Ohtuvayre, a breakthrough COPD treatment with rapid uptake since its 2024 launch.

Merck’s Maurice R. Hilleman Center for Vaccine Manufacturing photographed on Friday, Apr. 2, 2021, in Durham, N.C.·Raleigh News and Observer·Casey Toth/ctoth@newsobserver.com ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection ...

General market weakness greeted the closing bell on Thursday on both sides of the border, as suspense reigned over whether a ...

Biogen said it intends to invest an additional $2 billion to expand operations at its largest manufacturing facilities within North Carolina’s Research Triangle Park (RTP).

Regions face reduced federal research funding and shrinking venture capital for startups, though rankings stay consistent.